185 related articles for article (PubMed ID: 32173485)
1. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
Mohamed MZ; Zenhom NM
Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
[TBL] [Abstract][Full Text] [Related]
2. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
[TBL] [Abstract][Full Text] [Related]
3. Ameliorating effect of leukotriene receptor antagonist in multi-organ toxicity induced in rat offspring, a possible role for epidermal growth factor.
Abdelzaher WY; Rofaeil RR; Abdel-Hafez SMN; Atta M; Bahaa El-Deen MA; Ali DM
Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):183-191. PubMed ID: 33504223
[No Abstract] [Full Text] [Related]
4. Montelukast, a cysteinyl leukotriene receptor antagonist, exerts local antinociception in animal model of pain through the L-arginine/nitric oxide/cyclic GMP/K
Alizamani E; Ghorbanzadeh B; Naserzadeh R; Mansouri MT
Int J Neurosci; 2021 Oct; 131(10):1004-1011. PubMed ID: 32408781
[TBL] [Abstract][Full Text] [Related]
5. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
Said MM; Bosland MC
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of sepsis-induced pancreatic injury by leukotriene receptor antagonism via modulation of oxidative injury, and downregulation of inflammatory markers in experimental rats.
Hagar HH; Alhazmi SM; Arafah M; Bayoumy NM
Naunyn Schmiedebergs Arch Pharmacol; 2024 May; 397(5):3425-3435. PubMed ID: 37962585
[TBL] [Abstract][Full Text] [Related]
7. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
Al-Amran FG; Hadi NR; Hashim AM
Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
[TBL] [Abstract][Full Text] [Related]
8. Montelukast inhibits caspase-3 activity and ameliorates oxidative damage in the spinal cord and urinary bladder of rats with spinal cord injury.
Erşahin M; Çevik Ö; Akakın D; Şener A; Özbay L; Yegen BC; Şener G
Prostaglandins Other Lipid Mediat; 2012 Dec; 99(3-4):131-9. PubMed ID: 22986158
[TBL] [Abstract][Full Text] [Related]
9. Oxidative renal damage in pyelonephritic rats is ameliorated by montelukast, a selective leukotriene CysLT1 receptor antagonist.
Tuğtepe H; Sener G; Cetinel S; Velioğlu-Oğünç A; Yeğen BC
Eur J Pharmacol; 2007 Feb; 557(1):69-75. PubMed ID: 17173892
[TBL] [Abstract][Full Text] [Related]
10. Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
Venugopal N; Acharya P; Zarei M; Talahalli RR
Inflammopharmacology; 2019 Oct; 27(5):923-931. PubMed ID: 31309487
[TBL] [Abstract][Full Text] [Related]
11. Montelukast Ameliorates 2K1C-Hypertension Induced Endothelial Dysfunction and Associated Vascular Dementia.
Gupta S; Singh P; Sharma B
Curr Hypertens Rev; 2024; 20(1):23-35. PubMed ID: 38192137
[TBL] [Abstract][Full Text] [Related]
12. Montelukast attenuates interleukin IL-1β-induced oxidative stress and apoptosis in chondrocytes by inhibiting CYSLTR1 (Cysteinyl Leukotriene Receptor 1) and activating KLF2 (Kruppel Like Factor 2).
Li Z; Wang J; Ma Y
Bioengineered; 2021 Dec; 12(1):8476-8484. PubMed ID: 34565285
[TBL] [Abstract][Full Text] [Related]
13. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
[TBL] [Abstract][Full Text] [Related]
14. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
15. Possible Therapeutic Potential of Cysteinyl Leukotriene Receptor Antagonist Montelukast in Treatment of SARS-CoV-2-Induced COVID-19.
Dey M; Singh RK
Pharmacology; 2021; 106(9-10):469-476. PubMed ID: 34350893
[TBL] [Abstract][Full Text] [Related]
16. Role of cysteinyl leukotriene receptor-1 antagonists in treatment of experimentally induced mammary tumor: does montelukast modulate antitumor and immunosuppressant effects of doxorubicin?
El-Sisi Ael-D; Sokar SS; Salem TA; Abu Risha SE
Toxicol Ind Health; 2015 Nov; 31(11):1024-36. PubMed ID: 26499992
[TBL] [Abstract][Full Text] [Related]
17. Montelukast, a cysteinyl leukotriene receptor-1 antagonist protects against hippocampal injury induced by transient global cerebral ischemia and reperfusion in rats.
Saad MA; Abdelsalam RM; Kenawy SA; Attia AS
Neurochem Res; 2015 Jan; 40(1):139-50. PubMed ID: 25403620
[TBL] [Abstract][Full Text] [Related]
18. The Leukotriene Receptor Antagonist Montelukast Reduces Alpha-Synuclein Load and Restores Memory in an Animal Model of Dementia with Lewy Bodies.
Marschallinger J; Altendorfer B; Rockenstein E; Holztrattner M; Garnweidner-Raith J; Pillichshammer N; Leister I; Hutter-Paier B; Strempfl K; Unger MS; Chishty M; Felder T; Johnson M; Attems J; Masliah E; Aigner L
Neurotherapeutics; 2020 Jul; 17(3):1061-1074. PubMed ID: 32072462
[TBL] [Abstract][Full Text] [Related]
19. Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation.
Kawai Y; Narita Y; Yamawaki-Ogata A; Usui A; Komori K
Biomed Res Int; 2019; 2019():9104680. PubMed ID: 31263710
[TBL] [Abstract][Full Text] [Related]
20. The therapeutic role of lactobacillus and montelukast in combination with metformin in diabetes mellitus complications through modulation of gut microbiota and suppression of oxidative stress.
El-Baz AM; Shata A; Hassan HM; El-Sokkary MMA; Khodir AE
Int Immunopharmacol; 2021 Jul; 96():107757. PubMed ID: 33991997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]